The FDA cleared a PTSD treatment developed by Wave Neuroscience with Texas A&M researchers that uses personalized brain mapping to guide magnetic stimulation. Wave reported a 52% symptom reduction and 68% remission in a clinical trial, though full findings have not yet been released.